Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

Sanofi

Sanofi and Regeneron are set to give the development programme for their immuno-oncology candidate cemiplimab a $1bn boost.

The PD1 antibody is the ‘backbone’ of Sanofi’s checkpoint immuno-oncology strategy and a first regulatory submission - to the US FDA for cutaneous squamous cell carcinoma - is expected before April.

Sanofi and Regeneron’s investment in the drug will be increased to $1.64bn, almost a $1bn surge on their initial agreement back in 2015, and the companies said they would also equally fund the development of cemiplimab.

Additionally, the companies claimed they would be continuing its investment in other immuno-oncology programmes under its existing agreement.

Elias Zerhouni, MD, global head of R&D at Sanofi, said: “The ongoing collaboration between Sanofi and Regeneron underscores our commitment to partnering in the development of medicines to treat significant unmet medical needs.”

Meanwhile, the companies have also said they will provide an additional investment in the dupilumab development programme - for type 2 allergic diseases.

Zerhouni added: “The expansion of these clinical programmes, for both cemiplimab and dupilumab should enable us to quickly identify treatment opportunities in other disease areas.”

The injection of funds is intended to help accelerate planned new studies in chronic obstructive pulmonary disease (COPD), peanut allergy and grass allergy, as well as in patients who have multiple allergic conditions.

Finally, there will also be more money to accelerate and expand the development of the firms’ IL-33 antibody REGN3500, with studies expected to be conducted in atopic dermatitis, asthma and COPD.

Article by
Gemma Jones

9th January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

translational pharmacology medicine dose
The gold standard of scientific evidence
Will randomised controlled trials become a thing of the past?...
What does programmatic advertising mean for your pharma marketing strategy?
Senior Associate Consultant Jiayi Chen explains the benefits and pitfalls of programmatic advertising and reveals how it can impact return on investment in your marketing campaigns....
Discover who are the most engaging Pharma companies on Twitter
With engagement such a key performance metric we first created a weighted formula, incorporating likes, retweets and replies, which produced an engagement score for each account....

Infographics